Home » Topics » BioWorld Science

BioWorld Science
RSS

Lundbeck studies Lu-AG-06466 in phase I for fibromyalgia

Aug. 2, 2021

Trk-A inhibitor E-2511 restores cholinergic neurons in transgenic models of Alzheimer's disease

Aug. 2, 2021

Evolutionary modeling warns of COVID-19 vaccine resistance

Aug. 2, 2021

Topline phase II data with Sarconeos in sarcopenia

Aug. 2, 2021

RemeGen receives Australian ethics approval for phase I trial of ADC RC-118

Aug. 2, 2021

Changes in SavaDx and plasma P-tau181 confirm treatment effect of simufilam in AD

Aug. 2, 2021

Addition of GEN-1 to standard NAC shows safety and efficacy in phase I ovarian cancer study

Aug. 2, 2021

Deuterated GC-376 variants show efficacy in model of SARS-CoV-2 infection

Aug. 2, 2021

Jiangsu Simcere Pharmaceutical R&D discovers MAT2A inhibitors

Aug. 2, 2021

Beijing Kang Dini Pharmaceutical presents new IL-8 expression inhibitors

Aug. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...